Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Theriva Biologics, Inc. (TOVX : AMEX)

• Company Description    Theriva Biologics Inc. is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company's lead candidate includes VCN-01, SYN-004 and SYN-020. Theriva Biologics Inc., formerly known as Synthetic Biologics Inc., is based in ROCKVILLE, Md. Number of Employees: 22

• Price / Volume Information    Yesterday's Closing Price: $0.28 Daily Weekly Monthly 20 Day Moving Average: 44,244,040 shares Shares Outstanding: 23.41 (millions) Market Capitalization: $6.49 (millions) Beta: 0.54 52 Week High: $2.19 52 Week Low: $0.26 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -40.22% -41.79% 12 Week -40.13% -42.61% Year To Date -84.16% -86.15%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9605 MEDICAL CENTER DRIVE SUITE 270 - ROCKVILLE,MD 20850 USA ph: 301-417-4364 fax: 301-417-4367 ccalabrese@lifesciadvisors.com http://www.therivabio.com

• General Corporate Information    Officers Steven A. Shallcross - Chief Executive Officer; Chief Financial Officer a Jeffrey J. Kraws - Chairman John J. Monahan - Director Jeffrey Wolf - Director Jeffrey Wolf - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 87164U508 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 23.41 Most Recent Split Date: 8.00 (0.04:1) Beta: 0.54 Market Capitalization: $6.49 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.24 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 64.91% vs. Previous Quarter: -24.52% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -169.31 03/31/25 - -97.50 ROA 09/30/25 - - 06/30/25 - -82.41 03/31/25 - -55.31 Current Ratio 09/30/25 - - 06/30/25 - 1.19 03/31/25 - 1.53 Quick Ratio 09/30/25 - - 06/30/25 - 1.19 03/31/25 - 1.53 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 1.17 03/31/25 - 5.57 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.15 03/31/25 - 0.10 Debt-to-Capital 09/30/25 - - 06/30/25 - 13.37 03/31/25 - 8.85

Powered by Zacks Investment Research ©